Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Morphic Holding
(NASDAQ:MORF)
Intraday
$28.24
0.17
[0.61%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$28.24
0.17
[0.61%]
Last update: 11:26AM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings were released on Thu Apr 25th, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Morphic Holding Stock (NASDAQ:MORF)
Morphic Holding Stock (NASDAQ: MORF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 25, 2024
Morphic Therapeutic Ended First Quarter With $658.8M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into Second Half Of 2027
Benzinga Newsdesk
-
4 days ago
Morphic Holding Q1 2024 GAAP EPS $(0.91) Beats $(0.94) Estimate
Benzinga Newsdesk
-
4 days ago
Friday, March 08, 2024
Canaccord Genuity Maintains Buy on Morphic Holding, Lowers Price Target to $66
Benzinga Newsdesk
-
Mar 8, 2024, 12:16PM
Thursday, February 22, 2024
Recap: Morphic Holding Q4 Earnings
Benzinga Insights
-
Feb 22, 2024, 9:25AM
Friday, December 08, 2023
Citigroup Initiates Coverage On Morphic Holding with Buy Rating, Announces Price Target of $46
Benzinga Newsdesk
-
Dec 8, 2023, 7:45AM
Friday, November 03, 2023
Morphic Holding Q3 EPS $(0.73) Beats $(0.95) Estimate; Ended Q3 With $725.1M In Cash, Cash Equivalents, And Marketable Securities Providing Runway Into 2H Of 2027
Benzinga Newsdesk
-
Nov 3, 2023, 7:09AM
Thursday, October 12, 2023
Morphic Holding Inc Says As Of Sept 30, Preliminary Cash, Cash Equivalents And Marketable Securities Totaling About $725M
Benzinga Newsdesk
-
Oct 12, 2023, 9:00AM
Thursday, September 28, 2023
Where Morphic Holding Stands With Analysts
Benzinga Insights
-
Sep 28, 2023, 9:00AM
BMO Capital Maintains Outperform on Morphic Holding, Lowers Price Target to $52
Benzinga Newsdesk
-
Sep 28, 2023, 8:29AM
Tuesday, September 26, 2023
Morphic Holdings Announces CEO Dr. Praveen Tipirneni To Take Temporary Medical Leave Of Absence And To Return After He Recovers
Benzinga Newsdesk
-
Sep 26, 2023, 4:14PM
Monday, September 25, 2023
Gold Moves Lower; TransCode Therapeutics Shares Surge
Lisa Levin
-
Sep 25, 2023, 2:43PM
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
Vandana Singh
-
Sep 25, 2023, 2:30PM
Stifel Maintains Hold on Morphic Holding, Lowers Price Target to $33
Benzinga Newsdesk
-
Sep 25, 2023, 2:26PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Sep 25, 2023, 1:31PM
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Sep 25, 2023, 1:04PM
Nasdaq Turns Higher; SCYNEXIS Shares Plunge
Lisa Levin
-
Sep 25, 2023, 12:12PM
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Benzinga Insights
-
Sep 25, 2023, 11:00AM
Morphic shares are trading lower after BTIG downgraded the stock from Buy to Neutral.
Benzinga Newsdesk
-
Sep 25, 2023, 9:11AM
BTIG Downgrades Morphic Holding to Neutral
Benzinga Newsdesk
-
Sep 25, 2023, 6:29AM
Friday, September 22, 2023
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Sep 22, 2023, 2:22PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Sep 22, 2023, 1:31PM
Watching Morphic; Stifel Issues Note Titled 'UEG Abstract Endoscopic Improvement Rate Appears To Be Driving Weakness, Hard To Read Into Data Too Much Given Small Study'
Benzinga Newsdesk
-
Sep 22, 2023, 11:56AM
Watching Morphic; Traders Circulate 'MP009 Clinical Proof Of Principle And Favorable Tolerability Profile Shown With Orally Dosed MORF-057 As Induction Therapy For Moderately To Severely Active UC: Phase 2a Emerald-1 Study Results'; Shares Trading Lower
Benzinga Newsdesk
-
Sep 22, 2023, 11:36AM
Wednesday, August 09, 2023
Morphic Holding shares are trading lower after Stifel downgraded the stock from Buy to Hold and lowered its price target from $69 to $61.
Benzinga Newsdesk
-
Aug 9, 2023, 11:54AM
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Benzinga Insights
-
Aug 9, 2023, 11:00AM
Stifel Downgrades Morphic Holding to Hold, Lowers Price Target to $61
Benzinga Newsdesk
-
Aug 9, 2023, 5:05AM
Friday, August 04, 2023
Morphic Holding President and CEO Acquires 3,597 Shares After Exercising Company Stock Options
Benzinga Insights
-
Aug 4, 2023, 11:01AM
Thursday, August 03, 2023
Morphic Holding Q2 EPS $(0.92) Misses $(0.87) Estimate; Greater Than $730 Million In Cash And Equivalents; Extended Cash Runway Into Second Half Of 2027
Benzinga Newsdesk
-
Aug 3, 2023, 7:37AM
Friday, July 21, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Benzinga Insights
-
Jul 21, 2023, 11:00AM
Berenberg Initiates Coverage On Morphic Holding with Buy Rating, Announces Price Target of $75
Benzinga Newsdesk
-
Jul 21, 2023, 5:14AM
Friday, July 07, 2023
President and CEO at Morphic Holding Exercises Options Worth $207K
Benzinga Insights
-
Jul 7, 2023, 11:01AM
Thursday, June 15, 2023
President and CEO at Morphic Holding Exercises Options Worth $49K
Benzinga Insights
-
Jun 15, 2023, 11:01AM
Tuesday, June 06, 2023
Director at Morphic Holding Acquires Company Stock Options Worth 12,535 Shares
Benzinga Insights
-
Jun 6, 2023, 11:02AM
Thursday, May 11, 2023
Morphic Presents New Biomarker Data At DDW 2023 Supporting MORF-057 Program In Ulcerative Colitis
Happy Mohamed
-
May 11, 2023, 8:09AM
Wednesday, May 10, 2023
President at Morphic Holding Exercises Options Worth $934K
Benzinga Insights
-
May 10, 2023, 11:02AM
Friday, May 05, 2023
More Than $47M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Lisa Levin
-
May 5, 2023, 9:02AM
Wednesday, May 03, 2023
Morphic Therapeutic Raises $240M Via Secondary Share Sale Of 5.3M Shares At $45.00 Per Share
Benzinga Newsdesk
-
May 3, 2023, 3:27AM
Tuesday, May 02, 2023
Morphic Holding Plans Proposed Public Offering Of Its Common Stock; Terms Not Disclosed
Benzinga Newsdesk
-
May 2, 2023, 4:05PM
Wednesday, April 26, 2023
4 Analysts Have This to Say About Morphic Holding
Benzinga Insights
-
Apr 26, 2023, 11:00AM
RBC Capital Maintains Outperform on Morphic Holding, Raises Price Target to $80
Benzinga Newsdesk
-
Apr 26, 2023, 10:06AM
BMO Capital Maintains Outperform on Morphic Holding, Raises Price Target to $106
Benzinga Newsdesk
-
Apr 26, 2023, 8:30AM
Tuesday, April 25, 2023
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Apr 25, 2023, 1:33PM
Morphic shares were trading lower after the company reported worse-than-expected Q1 EPS and sales results.
Michael Horton
-
Apr 25, 2023, 12:14PM
Wells Fargo Maintains Overweight on Morphic Holding, Raises Price Target to $80
Benzinga Newsdesk
-
Apr 25, 2023, 12:09PM
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
-
Apr 25, 2023, 10:27AM
Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars
Vandana Singh
-
Apr 25, 2023, 9:54AM
Morphic Holding shares were trading higher after the company announced that its open-label EMERALD-1 Phase 2a study of MORF-057 met its primary endpoint in adults with moderate to severe ulcerative colitis.
Benzinga Newsdesk
-
Apr 25, 2023, 9:31AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Apr 25, 2023, 9:06AM
Morphic Holding Q1 EPS $(0.90) Misses $(0.81) Estimate, Sales $521.00K Miss $2.14M Estimate; $421M In Cash, Cash Equivalents & Marketable Securities, Extending Runway Into 2H Of 2026
Benzinga Newsdesk
-
Apr 25, 2023, 7:10AM
Morphic Therapeutic's Open-Label EMERALD-1 Phase 2a Study of MORF-057 Met Primary Endpoint In Adults With Moderate To Severe Ulcerative Colitis; MORF-057 Was Generally Well Tolerated With No Safety Signal Observed
Benzinga Newsdesk
-
Apr 25, 2023, 7:07AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch